← Back to Screener
Alpha Teknova, Inc. Common Stock (TKNO)
Price$4.56
Value ScoreC
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-10.49%
Price vs S&P 500 (4W)19.07%
VGM Score55.86
Market Capitalization$244.48M
All Metrics
Book Value / Share (Quarterly)$1.21
P/TBV (Annual)3.58x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-0.73%
Cash Flow / Share (Quarterly)$-0.17
Price vs S&P 500 (YTD)11.84%
Gross Margin (TTM)34.01%
Net Profit Margin (TTM)-41.07%
EPS (TTM)$-0.32
10-Day Avg Trading Volume0.22M
EPS Excl Extra (TTM)$-0.32
Revenue Growth (5Y)5.30%
EPS (Annual)$-0.32
ROI (Annual)-21.07%
Gross Margin (Annual)33.17%
Net Profit Margin (5Y Avg)-70.98%
Cash / Share (Quarterly)$0.33
Revenue Growth QoQ (YoY)13.09%
ROA (Last FY)-16.66%
Revenue Growth TTM (YoY)9.29%
EBITD / Share (TTM)$-0.28
ROE (5Y Avg)-30.55%
Operating Margin (TTM)-39.02%
Cash Flow / Share (Annual)$-0.18
P/B Ratio3.77x
P/B Ratio (Quarterly)2.39x
Net Income / Employee (Annual)$-109,200
EV / Revenue (TTM)6.06x
Net Interest Coverage (TTM)-23.23x
ROA (TTM)-16.34%
EPS Incl Extra (Annual)$-0.32
Current Ratio (Annual)4.58x
Quick Ratio (Quarterly)3.40x
3-Month Avg Trading Volume0.19M
52-Week Price Return-20.97%
Revenue / Employee (TTM)$264,600
Tangible BV / Share (Quarterly)$0.99
P/S Ratio (Annual)6.03x
Asset Turnover (Annual)0.39x
52-Week High$6.68
Operating Margin (5Y Avg)-72.56%
EPS Excl Extra (Annual)$-0.32
CapEx CAGR (5Y)-26.82%
26-Week Price Return-2.56%
Quick Ratio (Annual)3.44x
13-Week Price Return106.33%
Total Debt / Equity (Annual)0.19x
Current Ratio (Quarterly)4.59x
Enterprise Value$253.34M
Revenue / Share Growth (5Y)-8.08%
Asset Turnover (TTM)0.40x
Revenue / Employee (Annual)$256,500
Inventory Turnover (Annual)3.91x
Pretax Margin (Annual)-42.45%
Cash / Share (Annual)$0.40
3-Month Return Std Dev98.92%
Gross Margin (5Y Avg)34.07%
Net Income / Employee (TTM)$-108,700
ROE (Last FY)-25.09%
Net Interest Coverage (Annual)-20.77x
EPS Basic Excl Extra (Annual)$-0.32
Receivables Turnover (TTM)7.41x
Total Debt / Equity (Quarterly)0.20x
EPS Incl Extra (TTM)$-0.32
Receivables Turnover (Annual)9.07x
ROI (TTM)-20.51%
P/S Ratio (TTM)5.85x
Pretax Margin (5Y Avg)-73.62%
Revenue / Share (Annual)$0.76
Tangible BV / Share (Annual)$1.06
Price vs S&P 500 (52W)-45.34%
Year-to-Date Return20.00%
5-Day Price Return-15.08%
EPS Normalized (Annual)$-0.32
ROA (5Y Avg)-20.97%
Net Profit Margin (Annual)-42.59%
Month-to-Date Return-15.56%
Cash Flow / Share (TTM)$-1.21
EBITD / Share (Annual)$-0.30
Operating Margin (Annual)-41.90%
LT Debt / Equity (Annual)0.19x
ROI (5Y Avg)-25.97%
LT Debt / Equity (Quarterly)0.20x
EPS Basic Excl Extra (TTM)$-0.32
P/TBV (Quarterly)2.91x
P/B Ratio (Annual)2.96x
Inventory Turnover (TTM)4.10x
Pretax Margin (TTM)-40.87%
Book Value / Share (Annual)$1.28
Price vs S&P 500 (13W)98.08%
Beta0.68x
Revenue / Share (TTM)$0.78
ROE (TTM)-24.32%
52-Week Low$1.91
vGradeC
gGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.08est. -0.09
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.08
4.08
4.08
4.08
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TKNOAlpha Teknova, Inc. Common Stock | C | C | B | $4.56 |
| IDXXIdexx Laboratories Inc | D | B | C | $562.16 |
| LNTHLantheus Holdings, Inc | C | B | B | $100.98 |
| NNNNAnbio Biotechnology Class A Ordinary Shares | F | B | B | $22.99 |
| CLDXCelldex Therapeutics, Inc | F | F | C | $28.62 |
| NEOGNeogen Corp | C | C | B | $8.90 |
| NTLAIntellia Therapeutics, Inc | D | C | B | $13.54 |
| QDELQuidelOrtho Corporation Common Stock | C | C | D | $14.33 |
| ACHVAchieve Life Sciences, Inc. | F | F | B | $5.13 |
| MYGNMyriad Genetics Inc | C | C | C | $4.57 |
| IMDXInsight Molecular Diagnostics Inc. Common Stock | F | D | C | $5.24 |
About
Alpha Teknova Inc manufactures critical reagents used in the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The company offers two primary product lines—Lab Essentials and Clinical Solutions—comprised of pre-poured culture media plates, liquid microbial media, and molecular biology reagents for sample preparation and purification. Primary revenue is generated from the United States market.